アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Synthetic peptides to Human LILRB3, corresponding to C terminal amino acids 615-632, the peptide was post-synthetically modified to achieve desired antigenicity before coupling to a carrier protein.
Our Abpromise guarantee covers the use of ab82627 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500. Predicted molecular weight: 69 kDa.|
ab82627 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"